342 related articles for article (PubMed ID: 28465376)
1. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.
Neumiller JJ; Alicic RZ; Tuttle KR
J Am Soc Nephrol; 2017 Aug; 28(8):2263-2274. PubMed ID: 28465376
[TBL] [Abstract][Full Text] [Related]
2. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
3. Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
McGrath K; Edi R
Am Fam Physician; 2019 Jun; 99(12):751-759. PubMed ID: 31194487
[TBL] [Abstract][Full Text] [Related]
4. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L; Adler S
Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
[TBL] [Abstract][Full Text] [Related]
5. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
MacIsaac RJ; Thomas MC
Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
[No Abstract] [Full Text] [Related]
6. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
7. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
[TBL] [Abstract][Full Text] [Related]
8. A review on cardiovascular effects of newer hypoglycaemic medications.
Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
[TBL] [Abstract][Full Text] [Related]
9. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
10. [New oral hypoglycemic drugs in diabetic kidney disease].
Dylewska M; Graczyk M
Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
[TBL] [Abstract][Full Text] [Related]
11. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
[TBL] [Abstract][Full Text] [Related]
12. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
13. The effects of glucose-lowering therapies on diabetic kidney disease.
Agrawal V; Giri C; Solomon RJ
Curr Diabetes Rev; 2015; 11(3):191-200. PubMed ID: 25824237
[TBL] [Abstract][Full Text] [Related]
14. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
Game F
Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
[TBL] [Abstract][Full Text] [Related]
15. New hypoglycemic agents and the kidney: what do the major trials tell us?
Smyth B; Perkovic V
F1000Res; 2018; 7():. PubMed ID: 30542615
[TBL] [Abstract][Full Text] [Related]
16. [Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].
Granata A; Insalaco M; Di Nicolò P; Scarfia VR; Russo L; D'anna G; Lentini P; Fiorini F; Fatuzzo P
G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671840
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
18. Management of type 2 diabetes in chronic kidney disease.
Triozzi JL; Parker Gregg L; Virani SS; Navaneethan SD
BMJ Open Diabetes Res Care; 2021 Jul; 9(1):. PubMed ID: 34312158
[TBL] [Abstract][Full Text] [Related]
19. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
Seksaria S; Dutta BJ; Kaur M; Gupta GD; Bodakhe SH; Singh A
Curr Diabetes Rev; 2024; 20(6):e090823219597. PubMed ID: 37559236
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]